Introduction
Artificial chromosomes (ACs) are promising tools for gene therapy applications and possess many advantages over current vector systems. Similar to endogenous chromosomes, ACs can replicate and segregate autonomously without integration into the host chromosome. There are a number of artificial chromosomal systems currently under development, which fall under the broad headings of human artificial chromosomes (HACs), bacterial artificial chromosomes (BACs), yeast artificial chromosomes (YACs) and P1-derived artificial chromosomes (PACs). 1, 2 The major advantages of ACs are their potential to overcome problems in gene therapy protocols such as immunogenicity, insertional mutagenesis, oncogene activation or limitations in capacity for transgene expression. Whether the AC is an HAC, BAC, YAC or PAC, the basic requirement for an AC remains the same; the AC needs to be independently transferred to progeny cells in a dividing cell population, although continuing to maintain spatial and temporal levels of long-term transgene expression in specific cell types. 3 In addition, the AC should present no risk of cellular transformation or adverse immune system stimulation.
ACs can broadly be classified into two groups: linear ACs and circular ACs. If a linear form of AC is used, it requires a number of cis-acting elements for successful maintenance in vivo: (i) specific origins of replication, to maintain faithful DNA replication; (ii) a centromere, used for maintaining stability during the cell cycle and mitotic segregation and (iii) DNA capping telomeres, to maintain linearity. 4 Linear ACs have a potential for unlimited transgene capacity.
Circular ACs are vectors generally produced from BACs or PACs and have reasonably large transgene capacities, typically 300 kb, but have a maximum potential of 700 kb. Other advantages include ease of production and purification. 2, 5 Circular ACs require an origin of replication and an episomal maintenance element or a method of chromosome integration. In addition, if they are to be delivered by an infectious agent, the appropriate packaging signal needs to be included in the plasmid. These requirements are often fulfilled by the use of viral elements.
Advances in the purification of YACs
Production and purification of large size vectors such as YACs and HACs are problematic, not only because of low copy number vectors, which require purification from large volumes of culture, but also because of the physical properties of the vector.
A number of different protocols have recently been developed, which provide methodologies for producing YAC DNA, at concentrations typically 5-10 ng ml
À1
, and also reduces the likelihood of YAC sheering. 1, 6 One successful protocol involves separating purified yeast chromosomes (including the YAC) through pulse-field gel electrophoresis. The YAC band is then excised from the agarose matrix, turned vertically and embedded in a high percentage, low-melting point agarose. A second electrophoresis step concentrates the YACs into a single point. The YAC spot can then be melted releasing concentrated intact YACs, which can then be used for micro-injection. This methodology has proved successful for producing YACs suitable for the transgenesis of mice. 6 However, pulse-field gel electrophoresis can be time consuming and, therefore, a second YAC purification method has been developed for the purification of circular YACs containing genomic transcripts. This technique uses transformation-associated recombination (TAR) cloning and exonuclease chromatography purification. 7, 8 TAR cloning is based on co-transduction into yeast spheroplasts of isolated genomic DNA along with a vector construct that contains 5 0 and 3 0 homologous sequences specific for a gene of interest. Recombination between the vector and the target DNA establishes a YAC. This methodology allows entire genes and large chromosomal regions to be isolated from total genomic DNA by in vitro recombination in yeast without the need to construct YAC or BAC libraries. In particular, the authors have shown that this technique is able to produce circular YACs up to 120 and 150 kb in size, from 1.5 l cultures, producing yields in the region of 5-10 mg. In addition, the authors hypothesise that this protocol can be used to produce larger YACs, although TAR cloning may be limited to producing YACs of up to 250 kb in size. An advantage of this methodology is that it is quicker than the pulse-field gel electrophoresis purification method. In addition, it does not require the use of time consuming CsCL-EthBr gradients of other large DNA purification protocols. However, this system allows for the production and purification of vectors containing genomic regions that are potentially unstable in standard Escherichia coli vectors. This technique is, therefore, important as it may be suitable for carrying out investigations into the human genome that current BAC library-based shotgun protocols cannot achieve, as it is well documented that long inverted repeats, AT-rich sequences, are more stable in yeast than in E. coli. 1, 7 However, as these vectors are produced in an organism that has minimal methyltransferase activity, this may ultimately have implications in transgene expression in human beings, which have highly methylated DNA.
A new transposon-based technique for the generation of novel virus-based BACs
BAC and PAC vectors allow for quick, high yield, vector production (up to 500 mg DNA from 1 l culture). ACs can be produced from BACs and PACs by the inclusion of episomal maintenance elements, usually of viral origin. 2 In addition, the development of BAC technology has allowed the modification of large viral genomes to become a viable tool for generating self-packaging AC delivery vectors. A recent advance in the field of BAC generation has used a sequence-independent in vitro transposon-based methodology. 9 This technique allows the construction of viral BACs through the use of a Tn5 transposition system. In brief, the authors constructed a linear vector using a plasmid containing the necessary mini-F sequence required for BAC propagation in bacteria, the chloramphenicol resistance gene, a GFP fluorescent marker and two Tn5 transposase recognition sequences. The linear construct is then incubated with the wild-type viral genome in vitro allowing random transposition to occur in the presence of a transposase. The constructs are then propagated and screened using conventional BAC techniques. In vitro transposition alleviates the need for prior knowledge of the viral sequences, or the cloning of viral fragments, which may not be feasible in fastidious large-genome viruses. Importantly, this technique could be used to discover earlier unidentified viruses, which could be subsequently used as gene therapy vectors or ACs.
Amplicon virus-like particles present efficient delivery mechanisms for ACs
Although viral-based BACs have the potential to fulfil the aforementioned criteria of ACs, they still have limitations associated with immunogenicity, total nucleic acid capacity and, similar to all large constructs, transduction efficacy. These limitations have led to the production and continued development of amplicon systems. This is a unique way of creating a gene delivery tool that mimics the viral vector's ability for genome delivery and transgene expression, although minimising the exposure to harmful viral genes and increasing the packaging potential of the vector.
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Amplicons can be defined as plasmid-based vectors containing minimal viral coding sequences, which are able to be maintained in a dividing cell population, as a non-integrated episome. In addition, amplicon plasmids can be packaged into infectious virions, to form amplicon virus-like particles (ampVLPs). This is achieved by production of viral structural proteins, usually generated by some form of replication-deficient helper virus. To date, a number of amplicon systems have been produced based on the following viruses, particularly members of the herpesvirus family. These include Herpes simplex virus-1, Pseudorabies, Epstein-Barr virus and human cytomegalovirus. 2, 10 Recent advances in this field include the development of a recombinant g-2 herpesvirus saimiri (HVS) amplicon system, which has the potential to deliver upwards of 50-150 kb heterologous DNA. 10 HVS has potential to be used in a range of protocols, as it can infect a wide variety of cells including colorectal, breast, lung, liver, kidney and a variety of white blood cells, whilst being episomally maintained in a dividing cell population in both in vitro and in vivo studies. 11, 12 Important in vivo studies regarding the ability of HVS to deliver and express transgenes include the expression of bovine growth hormone in New World primates, as well as nude mouse tumour xenograft studies and intraperitoneal and intravenous HVS injection in mice. These studies determined systemic spread and persistence of the viral genome. The results thus far have shown that HVS is able to be delivered, maintained and express exogenous transgenes in the host after infection. 12 However, the HVS amplicon system currently has wildtype virus contamination, an issue that is faced by all amplicon systems in their infancy, this will need to be addressed before it can be used in gene therapy protocols.
Other amplicon research has focused on reducing wild-type virus contamination of ampVLP stocks by producing helper packaging cell lines, which supply all the lytic cascade and necessary structural genes in trans. The Herpes simplex virus-based amplicon systems are at the forefront of packaging cell line and amplicon technology, elucidating the requirements for minimal wild-type contamination and amplicon vector development. Recent work by Grant et al. 13 has produced HSV-1 packaging cell lines, which use replication defective HSVDICP4DICP27 vectors (JDTOZHE). ICP4 and ICP27 are genes essential in activating immediate early gene transcription of the viral lytic cascade. This work is important because it highlights the need to completely understand the kinetics of immediate early virus gene transcription when producing packaging cell lines. Production of an ICP4 and ICP27 supplemented JDTOZHE vero cell lines resulted in a threefold drop in recombinant amplicon titre, when compared against wild-type production. Insights into the unpredicted drop in titre arose when complementation studies revealed that supplemented ICP4 was delayed in expression by 8-10 h after vector transduction. This issue was addressed by using the ICP0 promoter, which resulted in higher induction levels, and faster kinetics of ICP4, as well as an additional 10-fold increase in vector yield. 13 
Hybrid AC technologies take advantage of the best traits of different vectors
The development and analysis of a wide array of gene therapy vectors has revealed that all vectors have their associated pros and cons (Table 1) . Therefore, it seems unlikely that there will be a single 'perfect' vector. As a consequence, work is ongoing to harness the best aspects of a multitude of vectors. Work by Moralli et al.
14 provides an example of combining the delivery efficacy of ampVLPs, though harnessing the natural maintenance mechanisms of HACs.
14 The authors constructed a HAC capable of being delivered by HSV-based ampVLPs ( Figure 1a ). Infectious delivery was achieved in both primary and cultured human cells including fibrosarcoma, glioma, kidney and lung. Infectious delivery resulted in the HAC providing GFP and hypoxanthinephosphoriboysltransferase transgene expression. Importantly, this technique is able to deliver the HAC to the cells of interest, at much higher efficacies (up to 10 4 times greater, m.o.i. 1-10) than earlier HAC lipofectamine transfections. 2 In addition, transgene expression was shown to be maintained and unchanged for a period of 3 Human artificial chromosomes S Macnab and A Whitehouse months. However, the authors do note that HAC-BACs were unstable in 293 and MRC-5V2 cells. This observed instability may be due to natural over-expression of the cancer inducing, anti-apoptotic chromosome regulating proteins AIM-1 and Topo II. 15 This highlights the fact that different HAC constructs may have varied suitability for different cell types and that vector design will have to compensate for different genetic backgrounds. However, this work presents a significant advance in the field of HAC delivery.
An additional technology that further blurs the line between HAC and BAC vectors is a novel method for linearising circular DNA, though stably maintaining it in E. coli. The protocol involves inserting a telomeric N15 telomere occupancy site (tos) fragment into the circular BAC. The tos site consists of a region of three inverted repeats, which get cleaved and rejoined to form a pair of capped telomeric ends on the linear DNA fragment by the N15 protelomerase 16 ( Figure 1b) . The capping of the linear DNA fragments inhibits the degradation of the DNA by enzymes such as RecA. This technology may provide a tool for studying the requirements of centromere formation. In addition, generation of linear HACs could be achieved by the inclusion of a-satellite DNA and inverted human telomeres into circular BACs. On cleavage of the tos site, a linear molecule will be produced with telomeres in the correct orientation. This methodology would generate large linear DNA producing a transgene capacity similar to other HACs, without having to perform purification and restriction digest protocols, thereby increasing the production yield and reducing DNA fragmentation.
A YAC-based method for genomic vector construction using TAR cloning Expression of genomic size loci allows for accurate transgene expression as the DNA sequence contains intronic and long-range control elements and features, which are essential for natural levels of protein expression. This is important in the clinical improvement of patients undergoing gene therapy protocols, because of the potential silencing of cDNA transgenes. 2 The construction of vectors containing and expressing genomic transcripts can, however, be problematic. This issue has recently been addressed using YAC technology. 8 This technique uses TAR cloning and exonuclease chromatography purification. The protocol relies on the incorporation of genomic fragments, in addition to a TAR-cloning vector containing a yeast selectable marker and yeast centromeric locus (into yeast spheroplasts) (Figure 2a) . Recombination events between the genomic region and TAR vector targeting sequences produce genomic transgene containing YACs. Yield of gene-positive clones varies from 1 to 5%. Currently, these vectors have applications in functional/comparative genomics, and long-range haplotyping because of the fact that multiple gene isolates are produced, potentially allowing for both parental alleles to be analysed. Importantly, this system may be able to efficiently produce vectors containing functional genes from individuals without a diseased genotype, which could then be further propagated for use in gene therapy protocols.
A novel method for BAC transgene molecular tagging
The construction of BAC vectors containing transgenes of interest, as well as the molecular tools for subsequent protein study, such as N-or C-terminal tagging, can involve many complex cloning strategies, which are time and resource intensive. Owing to the complexity of manipulating genomic loci, cDNAs are the method of choice for studying protein interactions. However, cDNA transgenes may not provide natural levels of expression or be completely translationally modified, and, therefore, study of genomic transcripts is preferable. Cloning of tagged genomic transcripts until recently was technically challenging. However, as genome sequencing projects advance, mapped BAC libraries are being produced for most model organisms. 17, 18 Poser et al. 18 have developed a pipeline methodology, which generates hundreds of transgenic constructs, and tens of transformed cell lines, per person, per month, termed as 'BAC TransgenOmics' 18 ( Figure 2b ). This elegant technique uses BAC recombination, producing N-or C-terminally tagged genomic transcripts contained within a BAC library. Initial Human artificial chromosomes S Macnab and A Whitehouse cultures are produced in a period of 24 h in a 96-well format. BAC TransgenOmics is suitable for studying protein localisation, tandem affinity purified proteinprotein interactions and chromatin immunoprecipitation (ChIP) assays. The authors have also shown that this technology can be used for studying the effects of proteins during growth and development by applying their BAC TrangenOmic protocol to embryonic stem (ES) cells. These technologies will allow for the easier study of genomic transcripts and associated proteins, and should, therefore, allow determination of the success of genomic loci expression of BAC delivered therapies to become a standardised high throughput technique.
BAC construct size may not affect in vivo vector delivery
Current research has shown that BAC plasmids can successfully express complete genomic loci; however, delivery of these constructs can be problematic. Recent studies have shown that somatic in vivo transduction of BACs is size independent, as long-term delivery and expression of genomic transcripts (4100 kb) in the liver has been shown after hydrodynamic mouse tail vein injection.
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Although the authors focused on gene expression in the liver, this technique has been shown to deliver BAC-expressing luciferase transgenes to organs such as the heart, lung, kidney, spleen and muscles albeit with a decrease in efficacy. Delivery of BACs is less efficient using this methodology compared with plasmid DNA; however, BAC DNA was found to have enhanced transgene expression compared with plasmid DNA. This research indicates that the largesized plasmids do not necessarily hinder transfection efficacies in vivo and that somatic delivery of BACs is a viable option and may, therefore, alleviate problems associated with virally mediated gene transfer. This data is surprising and important, as the majority of research reports low efficacies of large construct transfection in vitro. 
Advances using ACs to deliver a wide variety of transgenes including CFTR, FRDA and dystrophin
BACs are being developed to express a number of therapeutic genes. Recently, a BAC with a 250 kb insert was produced by red homologous (g-mediated) recombination expressing the CFTR gene, as well as 5 0 and 3 0 regulatory elements. Red recombination uses phageexpressed proteins to cause recombination and is restriction site and sequence size independent, thereby making this technique ideal for cloning genomic transcripts. Cystic fibrosis (CF) is a common, fatal genetic disease that affects 1 in 2500 Caucasians and is caused by mutation in the CFTR gene. Transfection of the CFTRBACs into murine CMT-93 cells showed that full length, correctly spliced CFTR mRNA could be detected after chemical transfection. However, these studies are limited to determining mRNA levels, because of the presence of endogenous mouse CFTR, thereby making studies at the protein level difficult. However, these vectors still have a large potential for correcting the phenotype of epithelia cells in a CF patient as the genomic transgene undergoes natural splicing events. Although expression of genomic CFTR has previously been achieved in YAC systems, this new CFTR-BAC expression system will allow for ease of vector propagation and purification, as well as controlled and tissue-specific transgene expression. 19 However, as with many protocols concerning CF, delivery of the vector is proving to be problematic. Nebulisers are currently used to alleviate symptoms of CF by delivering saline, drugs or water to the patient. This technology may be suitable for use with CFTR-BACs; however, BAC plasmids are very fragile and nebulisers will undoubtedly require modification to ensure correct cushioning of the BAC during delivery. One method may be to package the BAC in a viral coat and then use a nebuliser ensuring a physical coat, which will protect the BAC from mechanical stress.
HSV-1 amplicons are at the forefront of amplicon technology. They are able to deliver and express genomic loci in excess of 100 kb, and in vitro analysis shows that they are able to rescue phenotypes in cellular models of 17 A full colour version of this figure is available at the Gene Therapy journal online.
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S Macnab and A Whitehouse disease. 20 Recent advances in amplicon-derived therapeutics include delivery and long-term expression of the 135 kb genomic DNA insert containing the FRDA gene, encoding frataxin. This protein participates in the biogenesis of iron-sulphur clusters. Mutant FRDA genes result in Freidreich's ataxia, which affects 1-2 in 50 000 Caucasians. This disease mainly affects the central nervous system and cardiac tissue, and is characterised by gait, motor-neuron degeneration and cardiac hypertrophy. Current treatments have had some success in treating cardiac tissues, but have failed to treat the neurological disorders. 21 The HSV amplicon system allowed for production of high titre FRDA vectors (B3 Â 10 7 TU ml -1 ). Infection of cells with ampVLPs resulted in a significant restoration of the wild-type oxidative stress resistance phenotype in primary Freidreich's ataxia fibroblasts in vitro, which are otherwise extremely sensitive to oxidative conditions, suggesting a potential new avenue for gene therapy applications against this disease. Importantly this vector expresses the transgene at physiological conditions and has the advantage of using ampVLPs, which minimise host exposure to any adverse viral genes or proteins.
HACs are also showing promise in the field of molecular therapeutics. A recent study using a minichromosome-based HAC was shown to immortalise targeted cells. This may be beneficial for auto-, alloand xenotransplantion therapy. 22 The human telomerase reverse transcriptase transgene is responsible for inducing telomerase activity and stabilising telomere length, thereby increasing the life span of expressing cells. HACmediated transduction of human telomerase reverse transcriptase into human fibroblast cells (HFL-1) extended their ability to grow in culture for over 50 days, with a 10-fold increase in cell numbers. 22 This is the first demonstration of non-integrating ACs increasing the proliferative capacity of primary cells. Although successful, the HAC was transferred to the HFL-1 cells through microcell-mediated chromosome transfer (MMCT) (Figure 3) , and technologies will need to be improved in the field of HAC purification and delivery before this HAC becomes a viable tool in clinical gene therapy.
Another recent advance in HAC-mediated therapy is the development of an HAC vector capable of expressing the entire human dystrophin gene, designed for treatment of Duchenne muscular dystrophy (DMD). 23 DMD is a recessive X-linked, fatal disorder caused by the absence of dystrophin protein in skeletal muscle, brain, retina and smooth muscle. The disease affects 1 in 3500 males, and eventually leads to paralysis, fatigue and skeletal deformities. The Dystrophin gene spans 2.4 Mb and encodes a number of tissue-specific isoforms. Overor under-expression of these isoforms can lead to different muscular dystrophies. To address the issue of natural, isoform-specific gene regulation, the entire dystrophin gene was cloned, through loxP recombination, into a HAC produced from a truncated human chromosome 21. The resulting DYS-HAC was shown to be stable in human immortalised mesenchymal stem cells. In addition, production of chimeric mice containing the DYS-HAC vector were shown to express the appropriate isoforms in the correct tissues. However, the DYS-HAC vector still has limitations in its clinical application as HAC transfection was again achieved through the MMCT delivery method and research is required to determine a therapeutic proof of principle.
A second group has also managed to show the potential of ACs in the use of DMD gene therapy. 24 Hoen et al. 24 have generated human DMD (hDMD) mice Human artificial chromosomes S Macnab and A Whitehouse with intact and functional copies of the Dystrophin genomic transcript expressed from a YAC through fusion of DYS-YAC-containing yeast spheroblasts with mouse ES cells. Analysis revealed levels of Dystrophin similar to endogenous mouse Dystrophin. Moreover, the transgene was found to be integrated into mouse chromosome 5 and breeding studies provided functional proof of principle as the hDMD mice were crossed with dystrophin-deficient mice, which resulted in rescue of the lethal dystrophic phenotype, with all signs of muscular dystrophy disappearing. In addition, these studies have produced an animal model, which should allow direct research into molecular therapeutics or genetic studies of hDMD. However, as the YAC integrates into the host chromosome, this could lead to alteration of natural gene expression and genomic stability. These studies provide proof of principle that ACs can successfully be used to deliver and express large genomic constructs. In addition, ACs expressing genomic transcripts can produce the natural splice variants for each targeted tissue, something cDNA templates cannot achieve. This is important not only for dystrophin and CFTR, which have complicated regulation profiles requiring appropriate levels of functional isoforms to be produced, but also for other genomic transcripts, which have equally complex expression profiles.
ACs and stem-cell-based therapies
Investigations are currently ongoing to determine the potential of ACs for combined use with stem-cell therapeutics. One area of particular interest is the use of AC-containing stem cells as gene delivery vechicles. 25 Kinoshita et al. 25 have recently used human immortalised mesenchymal stem cells containing an HAC expressing the herpes simplex virus thymidine kinase (tk) gene to show that gene delivery causes a significant reduction in glioma mass compared with controls after ganciclovir treatment in nude mice models.
ACs can also be used in ex vivo stem-cell therapeutics. 26 Katona et al. 26 have recently shown ex vivo delivery of an AC expressing mouse or human derivatives of the galactocerebrosidase transgene through transfection into mouse ES cells. Galactocerebrosidase deficiency is responsible for Globoid cell leukodystrophy (also known as Krabbes's disease), which is associated with demyelination, severe gliosis and the presence of globoid cells. It is currently hypothesised that cell replacement therapy will be the best course of treatment for this genetic disease. To that end, chimeric mice were produced from ES cells, which expressed the galactocerebrosidase transgenes. Experimentation revealed that the life span of chimeric mice was increased twofold, showing the potential of ex vivo AC stem-cell therapies in the treatment of reversible genetic diseases and cancers through the production of modified replacement cells.
Although highly promising, ES-cell research is fraught with ethical issues. One proposed methodology to negotiate this issue is the use of multipotent germline (mGS) cells. 27 Recent work by Kazuki et al. 27 has shown functional restoration of a genetic deficiency in murine p53À/À mGS cells. This was achieved by delivering a human p53 expressing HAC (based on a truncated human chromosome 21) and delivered to ES and mGS cells through MMCT. Moreover, chimeric mice were produced using both ES and mGS cells, which on analysis of p53 isoforms showed correct splicing in different tissue types. In addition, in vitro studies indicated that HAC-mediated p53 expression resulted in a 10-fold increase in apoptosis in X-ray irradiated mGS cells, as well as the ability to differentiate into different embryonic germ layers after subcutaneous injection into nude mice, in contrast to control mGS cells. These experiments are important because they again show the potential for AC and stemcell therapeutic both in vivo, ex vivo and in vitro. Furthermore, they may negate ethical concerns over current research practices.
ACs have limitations in delivery and production
Each vector system has its limitations regarding their usefulness as an AC. BAC vectors are limited by their total transgene capacity, which although is not insignificant, cannot match the potential of YACs and HACs (Table 1; Figure 3 ). Transgene capacity and delivery mechanisms of BACs are being improved through the development of ampVLPs; however, these technologies are still hampered by the immunogenicity, which can be generated from associated viral gene expression, cellular debris or wild-type virus contamination. These issues will need to be addressed before these vectors are deemed to be truly safe.
HAC technology seems to be the most natural mechanism for expressing and maintaining transgenes; however, this technology is severely hampered in its clinical application through low transfection efficacies and purification technologies. The exception is satellite DNA-based HACs (SATACs). These HACs are generated by inclusion of a selectable marker and recombinant DNA into nuclear organisation regions and can be transfected using lipid-based reagents at efficacies, typically 0.1-1% or by the use of cationic lipids and high-frequency ultrasound (typically 12-53%, depending on cell type). To date, other forms of HACs can only be delivered to the target cell by the use of whole cell fusion or MMCT. 1, 2, 14 Purification is also problematic for HACs. Work is ongoing to develop protocols for HAC purification using flow cytometery. Currently, only murinebased SATACs have been successfully purified by flow cytometery. Features of these murine ACs include a large size (over 40 Mb in length) and a high satellite DNA content, which allows ease of identification and purification through staining techniques. However, the composition of murine-based SATACs is typically different from other HACs that are under development, which are much smaller, have a lower satellite DNA composition and are consequently difficult to distinguish from nuclear material. In addition, only murine-based SATAC chromosomes thus far have been reported to be routinely purified at reasonable rates (95% purity, 1 million vectors per hour). 1 Purification of high quantities of HACs will prove to be a major limiting factor before they can be routinely used in gene therapy applications.
Another potential problem associated with HACs is the large vector size. Most vectors are limited by the size HACs closer to 10 Mb maintained their ability to undergo mitotic segregation to a high fidelity. This presents a problem for the generation of HAC vectors, as a substantial amount of non-coding or 'stuffer' DNA may be required if only a single genomic transcript is being used in a therapeutic protocol. However, the choice of stuffer DNA must be carefully considered, as transgene expression studies using Adenovirus amplicon systems have revealed that transgene expression levels are affected by the type of stuffer DNA incorporated into the vector.
Prospects
As YACs stimulated ideas into the field of ACs, it is, therefore, rather fitting that there has been a flurry of developments to purify YACs at reasonably high yields. YACs, therefore, present an interesting prospect as gene therapy vectors in the clinic, as well as being commercially viable. However, like HACs, improvement in the methods for delivery to target cells are still required.
HACs have the ability to express multiple exogenous transgenes, in a non-integrated state, that uses natural cellular mechanisms of chromosomal maintenance. The recent success of HAC-mediated expression of large genomic transgenes suggests that these constructs will be suitable as gene therapy vectors in vivo. Furthermore, a significant step in delivering HACs to target cells has been taken by the development of the amplicon-based HAC.
14 This technology is important because it combines the infectious traits of the ampVLP, with the biosafety of an HAC, allowing for improvement in the delivery of HAC vectors.
Amplicon technology incorporating viral episomal maintenance elements and VLPs, presents a promising avenue of research for delivering and maintaining ACs. Moreover, these systems are showing great potential for expressing small genomic transcripts, providing cheap and quick methods of production and purification. Moreover, they are able to effectively target a wide variety of cells. However, further research is still required to remove wild-type contamination from ampVLP stocks.
The recent developments in AC technology present improved methods for the production, purification, delivery and natural transgene expression of genomicsized loci. These technologies are all steps forward in alleviating problems associated with synthetically produced cDNA. In addition, AC technology is proving to be highly compatible with stem-cell research. With further development, ACs could be used to improve the efficacy of gene therapy by providing physiologically appropriate expression of transgenes in vivo in target tissues.
